Laboratory Corporation of America Holdings

Monogram Biosciences, Inc.

Ali Mukherjee

Michael R Bates

Gordon Parry

Jeff Sperinde

Gundo Diedrich

Stephen J Williams

Jennifer W Cook

Laurie Goodman

Rajiv Dua

Hossein Salimi-Moosavi

Sailaja Pidaparthi

Yining Shi

Sharat Singh

Po-Ying Chan-Hui

Mojgan Haddad

John William Winslow

Gerald J Wallweber

Xueguang Jin

Weidong Huang

Jodi Weidler

Po-Ying Chan-Yui

Po-Ying Chan-hui

Uining Shi

Stephen John Williams

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.

Methods of determining patient response by measurement of HER-3 and P95

HER-3 antibodies and methods of use

The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

Methods for detecting receptor complexes comprising PI3K

Methods of determining patient response by measurement of Her-3

Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

Detecting and profiling molecular complexes

Growing community of inventors

Millbrae, CA, United States of America

Ali Mukherjee